Abbott (ABT)

• Market cap: $234B
• 1 day: 1.31%
• 5 days: 1.96%
• 1 month: 15.52%
• 3 months: 15.06%
• 6 months: 21.12%
• Year to date: 18.94%
• 1 year: 14.47%
• 5 years: 54.28%
• 10 years: 185.12%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.

Employees: 114,000

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

144% more first-time investments, than exits

New positions opened: 256 | Existing positions closed: 105

25% more call options, than puts

Call options by funds: $1.25B | Put options by funds: $999M

14% more funds holding in top 10

Funds holding in top 10: 63 [Q3] → 72 (+9) [Q4]

1.85% more ownership

Funds ownership: 75.61% [Q3] → 77.47% (+1.85%) [Q4]

3% more capital invested

Capital invested by funds: $150B [Q3] → $155B (+$4.6B) [Q4]

1% more funds holding

Funds holding: 2,848 [Q3] → 2,863 (+15) [Q4]

5% less repeat investments, than reductions

Existing positions increased: 1,067 | Existing positions reduced: 1,118

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $135 0% upside
• Avg. target: $142 6% upside
• High target: $158 17% upside

5 analyst ratings

• positive: 5 100%
• neutral: 0 0%
• negative: 0 0%

Barclays Matt Miksic 72% 1-year accuracy 28 / 39 met price target	17% upside $158	Overweight Maintained	27 Jan 2025
RBC Capital Shagun Singh 63% 1-year accuracy 44 / 70 met price target	0% upside $135	Outperform Reiterated	23 Jan 2025
Wells Fargo Lawrence Biegelsen 75% 1-year accuracy 3 / 4 met price target	1% upside $136	Overweight Maintained	23 Jan 2025
Stifel Rick Wise 64% 1-year accuracy 21 / 33 met price target	0% upside $135	Buy Maintained	23 Jan 2025
UBS Danielle Antalffy 69% 1-year accuracy 9 / 13 met price target	10% upside $148	Buy Maintained	23 Jan 2025